IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD) DEVICE

Gallant™ Dual-Chamber ICD

CDDRA500Q



Product Highlights

- Bluetooth® Low Energy (LE) communication enabling smartphone connectivity through data encryption
- 40J delivered energy safety shock option for enhanced safety margin
- DeFT Response[™] technology offers noninvasive programming options to optimize rescue therapy to each patient's unique physiology and changing conditions
- VF Therapy Assurance decreases time to treatment for arrhythmias in patients who are likely to be hemodynamically unstable
- Antitachycardia pacing (ATP) while charging and prior to charging in the VF zone extends the programming options for terminating tachyarrhythmias without a high-voltage shock
- ShockGuard™ technology with DecisionTx™
 programming designed to reduce inappropriate therapy
 and minimize the need for programming adjustments at
 implant
 - SecureSense[™] RV lead noise discrimination algorithm detects sustained lead noise and records short bursts of oversensing that would otherwise go unnoticed or potentially lead to one or more inappropriate shocks
 - Far Field MD[™] morphology discrimination and chamber onset discrimination enhance SVT and VT discrimination for reduced inappropriate therapies
- Sense *Ability*™ sensing algorithm feature provides the flexibility to fine-tune programming around T-wave oversensing without decreasing sensitivity

- DynamicTx[™] over-current detection algorithm automatically changes shock configurations to ensure delivery of high-voltage therapy when high current is detected
- MRI Ready device tested in combination with MR Conditional leads for full-body scans using a 1.5T or 3T (Tesla) field strength MRI Scanner*
- New battery provides higher capacity than previous QHR[†] batteries to offer superior longevity/volume ratio
- DF4 connector designed to streamline defibrillation connections into a single terminal pin and reduce the number of set screws
- Cold can programmability provides an additional RV-SVC shock configuration to decouple the can from the shocking vector parameters
- The CorVue[™] thoracic impedance feature measures transthoracic impedance changes over time to provide additional insight into the patient's heart failure condition
- Premature Atrial Contraction (PAC) Response to avoid pacing the atrium in a vulnerable zone
- Physiologic rate responsive AV Delay and PVARP
- Dual patient notification: audio notification through the device and visual notification via myMerlinPulse™ app

Ordering Information

Contents: Cardiac Pulse Generator

MODEL NUMBER	DIMENSIONS (H × W × T. MM)	WEIGHT (G)	VOLUME (CC)	CONNECTOR DEFIBRILLATION	CONNECTOR SENSE/PACE
CDDRA500Q	69 × 51 × 12	71	31	DF4	IS-1; DF4





Gallant™ Dual-Chamber ICD

CDDRA500Q

Models	CDDRA500Q		
Telemetry	Bluetooth® LE Communication		
Delivered/Stored Energy	40/45 J		
Volume	31 cc		
Weight	71 g		
Size	69 × 51 × 12 mm		
Defibrillation Lead Connection	DF4		
Atrial Sense/Pace Lead Connection	IS-1		
Ventricular Sense/Pace Lead Connection	DF4		
High-Voltage Can	Electrically active titanium can		
PARAMETER	SETTINGS		
AF Management			
AF Suppression™ Pacing	On; Off		
No. of Overdrive Pacing Cycles	15-40		
Maximum AF Suppression Rate	80-150 bpm		
Sensing/Detection			
SenseAbility™ Sensing Algorithm	Automatic Sensitivity Control adjustment for atrial and ventricular events		
Low Frequency Attenuation	On; Off		
Threshold Start	Post-Sensed: 50; 62.5; 75; 100%;		
	Post-Paced, Atrial: 0.2-3.0 mV		
Decay Delay	Post-Paced, Ventricular: Auto, 0.2-3.0 mV Post-Sensed: 0-220 ms		
Decay Delay	Post-Paced, Atrial: 0-220 ms		
	Post-Paced, Ventricular: Auto, 0-220 ms		
Ventricular Sense	125; 157 ms		
Refractory Detection Zones	2		
Detection Zones	3 zone programming — 1 zone, 2 zones or 3 zones (VT-1, VT-2, VF)		
SVT Discriminators	AV Rate Branch; Arrhythmia Onset (Chamber Onset or		
	Sudden Onset); Interval Stability; AV Association; Morphology		
	Discrimination (Far Field MD™ Morphology Discrimination or Original MD) with Automatic Template Update		
Monitor Mode	Detection, discrimination and diagnostics, no therapy delivery		
Worthor Wode	(VT or VT-1 zone)		
Discrimination Modes	On; Passive; Off		
SVT Upper Limit	150-240 bpm		
SVT Discrimination Timeout	20s-60 min; Off		
Reconfirmation	Continuous sensing during charging		
SecureSense™ RV Lead Noise	On; On with Timeout; Passive; Off		
Discrimination Algorithm VF Therapy Assurance	On; Off		
VF Therapy Assurance	Oli; Oli		
Antitachycardia Pacing Therapy			
ATP Configurations	Ramp; Burst; Scan; 1 or 2 schemes per VT zone		
ATP in VF Zone	ATP While Charging; ATP Prior to Charging; Off		
ATP Upper Rate Cutoff	150-300 bpm		
Burst Cycle Length	Adaptive (50%-100%); Fixed (200-550 ms)		
Min. Burst Cycle Length	150-400 ms		
Readaptive Number of Bursts	On; Off 1-15		

Number of Bursts Number of Stimuli 2-20 Add Stimuli per Burst ATP Pulse Amplitude On; Off 7.5 V independent from Bradycardia and Post-Therapy Pacing ATP Pulse Width 1.0 or 1.5 ms independently programmable from Bradycardia and Post-Therapy Pacing **High-Voltage Therapy**

DynamicTx™ Over-Current Detection Algorithm On; Off DeFT Response™ Technology High-Voltage Output Mode Programmable pulse width for P1/P2 and tilt Fixed Pulse Width; Fixed Tilt Biphasic; Monophasic Waveform RV Polarity Cathode (-): Anode (+) Electrode Configuration RV to Can; RV to SVC/Can; RV to SVC

Bradycardia Pacing

Permanent Modes Off; DDD(R); DDI(R); VVI(R); AAI(R)Off; DDD; DDI; VVI; AAI; AAT; DOO; VOO; AOO On; Passive; Off Temporary Modes Activity Sensor OII, FABSING; OII
Base Rate (bpm); Rest Rate (bpm); Maximum Tracking Rate (bpm); Maximum Sensor Rate (bpm); Paced AV Delay (ms); Sensed AV Delay (ms); Rate Responsive AV Delay; Hysteresis Rate (bpm); Rate Hysteresis with Search 0.25-7.5 V Programmable Rate and Delay Parameters Pulse Amplitude Pulse Width 0.05 ms, 0.1-1.5 ms On: Off

40; 45; ... 135 bpm Low; Medium; High; Off

On; Off

Ventricular AutoCapture™ Pacing System ACap™ Confirm Feature

On; Monitor; Off QuickOpt™ Timing Cycle Optimization Sensed/Paced AV delay Auto Mode Switch (AMS) DDI(R); VVI(R); Off Atrial Tachycardia Detection Rate 110-300 bpm

AMS Base Rate Rate Responsive PVARP Rate Responsive V Pace Refractory

On: Off PAC Response PAC Response Interval 200-400 ms

IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD) DEVICE

PMT Detection/Termination Ventricular Intrinsic Preference Atrial Pace; Passive; Off On (50-200 ms); Off

Post-Therapy Pacing (Independently Programmable from Bradycardia and ATP)

Post-Shock Pacing Mode AAI: VVI: DDI: DDD: Off 30-100 bpm Post-Shock Base Rate

Post-Shock Pacing Duration 0.5; 1; 2.5; 5; 7.5; or 10 min; Off

Device Testing/Induction Methods

DC Fibber™ Induction Method 0.5-5.0 sec Pulse Duration Burst Fibber Cycle Length

20-100 ms

Noninvasive Programmed Stimulation (NIPS) 2-25 stimuli with up to three extra stimuli

Patient Notifiers

Programmable Notifiers (On; Off)

BatteryAssurance Talert, Possible HV circuit damage, HV charge timeout, Long charge time for Capacitor Maintenance, Device at ERI, Atrial pacing lead impedance out of range. Ventricular pacing lead impedance out of range, High-voltage lead impedance out of range, AT/AF Episode duration, AT/AF Burden, High ventricular rate during AT/AF, SecureSense lead noise detection, Non-sustained restriction coverses in Matricular vaccing researches.

ventricular oversensing, Ventricular pacing percentage greater than limit

Device Parameter Reset On Entry into Backup VVI Mode On

Auditory Duration 2; 4; 6; 8; 10; 12; 14; 16 sec

Number of Audio alerts per Notification Number of Notifications 1-16 10; 22 hours Time Between Notifications

Electrograms and Diagnostics

Stored Electrograms

30 minutes (2 user programmable + discrimination channel), up to one minute programmable pre-trigger data per VT/VF electrograms; additional triggers include lead noise detection, non-sustained ventricular oversensing, morphology template updates, atrial episode, PMT termination, PAC response, magnet reversion, noise reversion

Diagram of therapies delivered Therapy Summary

Episodes Summary Directory listing of up to 60 episodes with access to more details including stored electrograms

Lifetime Diagnostics History of bradycardia events and device-initiated charging AT/AF Burden Trend

Trend data and counts Ventricular HV Lead Impedance Multi-Vector Trend Data Histograms and Trends

Multi-Vector Trend Data
Event Histogram; AV Interval Histogram; Mode Switch or
AT/AF Duration Histogram; Peak Filtered Atrial Rate during
atrial arrhythmia Histogram; Atrial Heart Rate Histogram;
Ventricular Heart Rate Histogram; AT/AF Burden; Exercise
and Activity Trending; V Rates during AMS; DirectTrend™

reports up to Iver.

reports up to 1 year Information regarding PMT detections

Pacing lead impedances; high-voltage lead impedances; and signal amplitudes Real-Time Measurements (RTM)

CorVue Thoracic Impedance On; Off

CorVue Thoracic Impedance Threshold 8-18 days

MRI Settings

PMT Data

Tachy Therapy Disabled

DOO; VOO; AOO; Pacing Off MRI Mode 30-100 bpm MRI Base Rate MRI Paced AV Delay 25-120 ms MRI Pulse Amplitude MRI Pulse Width 5.0 or 7.5 V 1.0 ms MRI Pulse Configuration Bipolar

MRI Timeout Off; 3; 6; 9; 12; 24 hours

MRI Scan Parameters

LEAD MODEL	MAGNET (TESLA)	RF TRANSMIT CONDITIONS	SCAN REGION
Durata™ Defibrillation Lead			
7120Q (lead lengths: 58, 65 cm) 7122Q (lead lengths: 58, 65 cm)	1.5T / 3T		
Optisure™ Lead			
LDA220Q (lead lengths: 58, 65 cm) LDA210Q (lead lengths: 58, 65 cm)	1.5T / 3T	Normal Operating	Full-body
Tendril™ STS Pacing Lead		Mode	
2088TC (lead lengths: 46, 52 cm)	1.5T / 3T		
Tendril MRI™ Lead			
LPA1200M (lead lengths: 46, 52 cm)	1.5 T		

[†] For additional information about specific MR Conditional ICDs and leads, including scan parameters, warnings, precautions, adverse conditions to MRI scanning, and potential adverse events, please refer to the Abbott MRI Ready Systems Manual at medical.abbott/manuals.



Rx Only Intended Use: The Implantable Cardioverter Defibrillator (ICD) devices are intended to provide ventricular antitachycardia pacing and ventricular cardioversion/defibrillation.

The myMerlinPulse™ mobile application is intended for use by people who have an Abbott Medical implanted heart device and access to a mobile device. The app provides remote monitoring capability of the implanted heart device by transmitting information from the patient's implanted heart device to the patient's healthcare provider.

Indications: The ICD devices are indicated for automated treatment of life-threatening ventricular arrhythmias.

In addition, dual chamber ICD devices with the AT/AF detection algorithm are indicated in patients with atrial tachyarrhythmias or those patients who are at significant risk of developing atrial tachyarrhythmias

MR Conditional ICDs are conditionally safe for use in the MRI environment when used in a complete MR Conditional system and according to instructions in the MRI-Ready Systems manual. Scanning under different conditions may result in severe patient injury, death or device malfunction.

The myMerlinPulse™ mobile application is indicated for use by patients with supported Abbott Medical implanted heart devices.

Contraindications: Contraindications for use of the pulse generator system include ventricular tachyarrhythmias resulting from transient or correctable factors such as drug toxicity, electrolyte imbalance, or acute myocardial infarction

The myMerlinPulse™ mobile application is contraindicated for use with any implanted medical device other than supported Abbott Medical implanted heart devices.

Adverse Events: Possible adverse events associated with the implantation of the pulse generator system include the following: Arrhythmia (for example, accelerated or induced), Bradycardia, Cardiac or venous perforation, Cardiac tamponade, Cardiogenic shock, Death, Discomfort, Embolism, Endocarditis, Erosion, Exacerbation of heart failure, Excessive fibrotic tissue growth, Extracardiac stimulation (phrenic nerve, diaphragm, pectoral muscle), Extrusion, Fluid accumulation within the device pocket, Formation of hematomas, cysts, or seromas, Heart block, Hemorrhage, Hemothorax, Hypersensitivity, including local tissue reaction or allergic reaction, Infection, Keloid formation, Myocardial damage, Nerve damage, Occlusion/Thrombus, Pericardial effusion, Pericardialis, Pneumothorax, Pulmonary edema, Syncope, Thrombosis, Valve damage. Complications reported with direct subclavian venipuncture include pneumothorax, hemothorax, hemothorax, laceration of the subclavian artery, arteriovenous fistula, neural damage, thoracic duct injury, cannulation of other vessels, massive hemorrhage and rarely, death. Among the psychological effects of device implantation are imagined pulsing, depression, dependency, fear of premature battery depletion, device malfunction, inappropriate pulsing, shocking while conscious, or losing pulse capability. Possible adverse device effects include complications due to the following: Abnormal battery depletion, Conductor fracture, Device-programmer communication failure, Elevated or rise in defibrillation/cardioversion threshold, Inability to defibrillate or pace, Inability to interrogate or program due to programmer or device malfunction, Incomplete lead connection with pulse generator, Inhibited therapy including defibrillation and pacing, Inappropriate therapy (for example, shocks and antitachycardia pacing [ATP] where applicable, pacing), Interruption of function due to electrical or magnetic interference, Intolerance to high rate pacing (for example, shocks and antitachycardia pacing [ATP] wher contraindications, warnings, precautions and potential adverse events.

No potential adverse events have been identified with use of the myMerlinPulse™ mobile application.

